Recent Finacing
Recent Raise
Grid Therapeutics develops patient-derived, tumor-specific IgG antibodies using single-B-cell genomic discovery to produce GT103, an IgG3 targeted immunotherapy advanced toward first-in-human clinical testing.
Focus Areas
Recent Investors
Funding rounds
Investors
See the team members at Grid Therapeutics.
